This document provides a business update from CombiMatrix Corporation for January 2014. It summarizes CombiMatrix's strategy of providing clinical support services in prenatal genetics, pediatric disorders, and oncology using microarray platforms, karyotyping, and FISH technologies. The management team is highlighted, including the President & CEO who has extensive experience in diagnostic sales. Recent highlights include a partnership with Sequenom to market prenatal microarray testing and third quarter 2013 financial results.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section showing the performance of The Sarian Group Index which tracks publicly traded life sciences companies in the region against benchmarks. It lists top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards a strategic sale or IPO.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
This 3 sentence summary provides the high level and essential information from the document:
The document discusses how pharmaceutical companies can develop effective key opinion leader (KOL) relationship management (KRM) strategies and plans. It explains that while customer relationship management (CRM) focuses on immediate prescription generation, KRM aims to create long-term brand perception and influence among target audiences through KOL activities. The document also outlines some of the key elements that should be included in a robust KRM strategy and plan, such as KOL identification, customized engagement programs, and impact measurement.
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
The document discusses the evolution of medical science liaison (MSL) teams from the 1980s to present day. It describes how MSL teams initially focused on post-marketing activities but now also contribute value to clinical drug development processes like trial design and identification of new indications. The document provides examples of how MSL teams have helped pharmaceutical companies gain regulatory approval faster, lower development costs, and increase drug revenues.
Method, tools and recommendations to boost Medical Science Liaisons Competence and performance.
Presentation of best practices to manage key opinion leaders
Cancer Genetics reported on its Q4 and full year 2016 earnings. Key highlights included 50% revenue growth in 2016 to $27 million, driven by increases in biopharma, clinical, and discovery services. The company realized operational efficiencies through integration of acquisitions, reducing expenses. However, the company reported a net loss of $15.8 million for 2016. In Q4 2016, revenue increased 32% to $7.2 million while expenses decreased, though the company reported a net loss of $2.8 million. Additionally, Cancer Genetics completed a $12 million debt refinancing to repay existing debt and access additional capital.
Medical affairs department for small organizationDr. Zubair Ali
The document summarizes the drug development process and the role of medical affairs departments within pharmaceutical companies. It discusses the various phases of clinical drug trials from phase I to phase IV. It then outlines the structure and responsibilities of medical affairs, including clinical research, pharmacovigilance, medical information services, statistics management, and providing medical support to marketing and sales teams. A key part of medical affairs is the medical science liaison program which aims to educate medical professionals and support clinical trial recruitment through relationship building.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section showing the performance of The Sarian Group Index which tracks publicly traded life sciences companies in the region against benchmarks. It lists top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards a strategic sale or IPO.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
This 3 sentence summary provides the high level and essential information from the document:
The document discusses how pharmaceutical companies can develop effective key opinion leader (KOL) relationship management (KRM) strategies and plans. It explains that while customer relationship management (CRM) focuses on immediate prescription generation, KRM aims to create long-term brand perception and influence among target audiences through KOL activities. The document also outlines some of the key elements that should be included in a robust KRM strategy and plan, such as KOL identification, customized engagement programs, and impact measurement.
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
The document discusses the evolution of medical science liaison (MSL) teams from the 1980s to present day. It describes how MSL teams initially focused on post-marketing activities but now also contribute value to clinical drug development processes like trial design and identification of new indications. The document provides examples of how MSL teams have helped pharmaceutical companies gain regulatory approval faster, lower development costs, and increase drug revenues.
Method, tools and recommendations to boost Medical Science Liaisons Competence and performance.
Presentation of best practices to manage key opinion leaders
Cancer Genetics reported on its Q4 and full year 2016 earnings. Key highlights included 50% revenue growth in 2016 to $27 million, driven by increases in biopharma, clinical, and discovery services. The company realized operational efficiencies through integration of acquisitions, reducing expenses. However, the company reported a net loss of $15.8 million for 2016. In Q4 2016, revenue increased 32% to $7.2 million while expenses decreased, though the company reported a net loss of $2.8 million. Additionally, Cancer Genetics completed a $12 million debt refinancing to repay existing debt and access additional capital.
Medical affairs department for small organizationDr. Zubair Ali
The document summarizes the drug development process and the role of medical affairs departments within pharmaceutical companies. It discusses the various phases of clinical drug trials from phase I to phase IV. It then outlines the structure and responsibilities of medical affairs, including clinical research, pharmacovigilance, medical information services, statistics management, and providing medical support to marketing and sales teams. A key part of medical affairs is the medical science liaison program which aims to educate medical professionals and support clinical trial recruitment through relationship building.
Bill Hatfield has over 20 years of experience in oncology leadership, marketing, and commercial development. He has led the commercial development and US launches of 10 oncology products, including Velcade at Millennium Pharmaceuticals. Most recently, he was Vice President of New Products Strategy at Sanofi Oncology, where he established a team to provide strategic input and support business development efforts to rebuild Sanofi's oncology pipeline.
Educating the Market--Creating Value Through Support of Continuing Medical Ed...Best Practices
This case study highlights key marketing activities that contributed to Requip’s commercial success. Individually the activities were well planned and executed but in combination produced a synergistic effect that catapulted a low profile condition into the minds of patients and scripts of physicians
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
Medical Affairs Leadership Summit, Key APAC Insights - August 2016Lynn Okamoto
1) The document summarizes insights from a medical affairs leadership summit in Asia Pacific that discussed defining medical affairs visions and missions, transforming field medical teams, the role of medical affairs in late-stage development and launch readiness.
2) Key topics included adapting medical affairs visions to evolving healthcare landscapes, enhancing field teams' business skills and ability to generate insights, challenges generating real-world evidence in diverse Asia Pacific markets, and ensuring adequate planning and resources for medical affairs involvement in launches.
3) Attendees discussed how medical affairs can demonstrate greater strategic value by engaging more stakeholders, generating regional insights, and involving earlier in product development and launches.
- Eric Pertzborn has over 15 years of experience in healthcare administration, including his current role as Clinic Director at the University of Illinois at Chicago since 2005.
- As Clinic Director, he increased the clinic's financial production by 336% through initiatives like Six Sigma and implementing a new $2.3 million revenue source.
- He has extensive experience with operations management, process improvement, budgeting, cost management, marketing, and team leadership in healthcare settings.
Bill Hatfield is a biotechnology executive with over 20 years of experience in oncology leadership, commercial development, and marketing. He has led the commercial development and US launches of 10 oncology products, including Velcade at Millennium Pharmaceuticals where he achieved $100 million in sales in the first year. Currently he is Senior Vice President of Commercial Development at Karyopharm Therapeutics, leading the commercialization of Selinexor as a potential therapy for hematological malignancies and solid tumors.
From Research to Revenue IV: Capturing Business Opportunities in AsiaGHBN
A full collection of the presentations made Wednesday, December 3, 2008 at Mississauga Living Arts Centre for From Research to Revenue IV: Capturing Business Opportunities in Asia.
1) Express Scripts is the largest pharmacy benefit manager (PBM) in the US but faces slowing growth as its core business reaches maturity. It lacks a compelling valuation and trades around its estimated fair value.
2) Intensifying competition in the pharmaceutical industry may lead to price wars that threaten Express Scripts' business model of aggressively negotiating lower drug prices.
3) Given Express Scripts' maturing business and risks to future growth, investors have an opportunity to realize gains by selling their shares in the company.
The document discusses setting up and managing medical affairs teams in the Asia Pacific region. It outlines the role of medical affairs as providing medical leadership, generating and disseminating data, and ensuring pharmacovigilance and compliance. It also discusses establishing the right balance of resources and competencies on regional teams. Key challenges for regional medical affairs teams in Asia Pacific include recruiting talent given diversity across countries, adapting to different healthcare systems, and meeting varied patient and HCP expectations.
Alison McNair is an established sales leader with over 11 years of experience at GlaxoSmithKline leading respiratory sales teams across multiple states. She has a proven track record of exceeding sales goals and cultivating high-performing teams. Her expertise includes business development, contract negotiations, compliance, and developing new hires. McNair has consistently grown market share for respiratory products and launched new vaccines and drugs. She is pursuing Six Sigma certification to further enhance her leadership skills.
Apollo Medical Holdings (“ApolloMed” or “AMEH”) is a leading population management and physician healthcare delivery company. Apollo provides medical management and care coordination for over 1,000 providers and 40,000 patients; including many senior patients. In addition, Apollo doctors provide care for over 100,000 patients in hospitals, facilities, and clinics. ApolloMed’s integrated healthcare delivery platform is comprised of ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group IPA (Independent Physician Association), Apollo Palliative Services, and ApolloMed Care Clinics. ApolloMed is able to provide high quality, cost-effective care, and its revenue model ranges from traditional volume-based payments to taking full clinical and financial risk for pools of patients.
Apollo Medical Holdings (ApolloMed) is a leading integrated healthcare company providing solutions to hospitals, health plans, physicians, and other health providers to provide cost-effective, quality healthcare. We work with providers and hospitals to coordinate care with local primary care physicians to reduce preventable hospital admissions and re-admissions, best in class patient centric care, and avoidable emergency room visits.
Medical Affairs, as a function, sits at a crossroads in the pharmaceutical industry. The department is expected to act as a bridge between the commercial and scientific arms of an organization. Medical Affairs is further tasked with being the conduit of information between the company and external stakeholders, bringing efficacy and safety data to the medical community as well as gathering insights from the medical community to share internally. All responsibilities must be undertaken while keeping in mind strict regulatory controls and ensuring that medical data are interpreted appropriately.
ISR has designed this report to be used as a benchmarking tool for companies to compare their Medical Affairs functions to those of Top 50 pharmaceutical organizations.
See more: http://bit.ly/medaffairs
The document outlines a business plan for starting a medical device supply company in South Africa. It provides an overview of the market opportunity in South Africa, including growth rates in the medical device industry and the types of products sold. It then outlines 7 steps to starting the business, including selecting a niche market, obtaining necessary licenses and permits, setting up inventory, and marketing strategies. Key points about the South African market such as the size of the public and private hospital sector and available financing options are also summarized.
Easy-to-use web-based database enables users to generate custom reports based upon any combination of these variables: Brand, Therapeutic area, Company, Country and Time period.
Ambiance Ventures - Access to Emerging MarketsJay Nadkarni
The company provides market development and consulting services focused on emerging markets, especially those receptive to new life science technologies. It has offices in Brazil, Estonia, Finland, South Korea, and India to handle operations in Latin America, Europe, and Asia. The company has strong connections and relationships in various markets that enable it to expedite product launches and other business needs. It offers services such as market assessments, licensing opportunities, and developing partnerships and commercialization plans to help life science companies enter emerging markets.
Opexa Therapeutics is developing Tcelna, a precision immunotherapy for the treatment of multiple sclerosis (MS). Tcelna consists of attenuated antigen-specific T-cell clones that are designed to program the immune system to target pathogenic myelin reactive T-cells (MRTC) that cause damage in MS. Opexa has completed enrollment in a Phase IIb clinical trial of Tcelna in secondary progressive MS (SPMS) and expects top-line data in mid-2016. The company has an option agreement with Merck for the development and commercialization of Tcelna in MS that could provide up to $220 million in payments if certain development and sales milestones are achieved.
Genius Brands International provides children's entertainment content across multiple platforms. It owns established brands like Baby Genius that have found success in television, online, mobile, and consumer products. The company aims to produce content that is both entertaining and enriching for kids. It has an experienced management team with decades of experience in the children's entertainment industry. Genius Brands sees opportunities to expand its brands internationally and introduce new content partnerships with figures like Warren Buffett, Thomas Edison, and Stan Lee.
Bill Hatfield has over 20 years of experience in oncology leadership, marketing, and commercial development. He has led the commercial development and US launches of 10 oncology products, including Velcade at Millennium Pharmaceuticals. Most recently, he was Vice President of New Products Strategy at Sanofi Oncology, where he established a team to provide strategic input and support business development efforts to rebuild Sanofi's oncology pipeline.
Educating the Market--Creating Value Through Support of Continuing Medical Ed...Best Practices
This case study highlights key marketing activities that contributed to Requip’s commercial success. Individually the activities were well planned and executed but in combination produced a synergistic effect that catapulted a low profile condition into the minds of patients and scripts of physicians
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
Medical Affairs Leadership Summit, Key APAC Insights - August 2016Lynn Okamoto
1) The document summarizes insights from a medical affairs leadership summit in Asia Pacific that discussed defining medical affairs visions and missions, transforming field medical teams, the role of medical affairs in late-stage development and launch readiness.
2) Key topics included adapting medical affairs visions to evolving healthcare landscapes, enhancing field teams' business skills and ability to generate insights, challenges generating real-world evidence in diverse Asia Pacific markets, and ensuring adequate planning and resources for medical affairs involvement in launches.
3) Attendees discussed how medical affairs can demonstrate greater strategic value by engaging more stakeholders, generating regional insights, and involving earlier in product development and launches.
- Eric Pertzborn has over 15 years of experience in healthcare administration, including his current role as Clinic Director at the University of Illinois at Chicago since 2005.
- As Clinic Director, he increased the clinic's financial production by 336% through initiatives like Six Sigma and implementing a new $2.3 million revenue source.
- He has extensive experience with operations management, process improvement, budgeting, cost management, marketing, and team leadership in healthcare settings.
Bill Hatfield is a biotechnology executive with over 20 years of experience in oncology leadership, commercial development, and marketing. He has led the commercial development and US launches of 10 oncology products, including Velcade at Millennium Pharmaceuticals where he achieved $100 million in sales in the first year. Currently he is Senior Vice President of Commercial Development at Karyopharm Therapeutics, leading the commercialization of Selinexor as a potential therapy for hematological malignancies and solid tumors.
From Research to Revenue IV: Capturing Business Opportunities in AsiaGHBN
A full collection of the presentations made Wednesday, December 3, 2008 at Mississauga Living Arts Centre for From Research to Revenue IV: Capturing Business Opportunities in Asia.
1) Express Scripts is the largest pharmacy benefit manager (PBM) in the US but faces slowing growth as its core business reaches maturity. It lacks a compelling valuation and trades around its estimated fair value.
2) Intensifying competition in the pharmaceutical industry may lead to price wars that threaten Express Scripts' business model of aggressively negotiating lower drug prices.
3) Given Express Scripts' maturing business and risks to future growth, investors have an opportunity to realize gains by selling their shares in the company.
The document discusses setting up and managing medical affairs teams in the Asia Pacific region. It outlines the role of medical affairs as providing medical leadership, generating and disseminating data, and ensuring pharmacovigilance and compliance. It also discusses establishing the right balance of resources and competencies on regional teams. Key challenges for regional medical affairs teams in Asia Pacific include recruiting talent given diversity across countries, adapting to different healthcare systems, and meeting varied patient and HCP expectations.
Alison McNair is an established sales leader with over 11 years of experience at GlaxoSmithKline leading respiratory sales teams across multiple states. She has a proven track record of exceeding sales goals and cultivating high-performing teams. Her expertise includes business development, contract negotiations, compliance, and developing new hires. McNair has consistently grown market share for respiratory products and launched new vaccines and drugs. She is pursuing Six Sigma certification to further enhance her leadership skills.
Apollo Medical Holdings (“ApolloMed” or “AMEH”) is a leading population management and physician healthcare delivery company. Apollo provides medical management and care coordination for over 1,000 providers and 40,000 patients; including many senior patients. In addition, Apollo doctors provide care for over 100,000 patients in hospitals, facilities, and clinics. ApolloMed’s integrated healthcare delivery platform is comprised of ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group IPA (Independent Physician Association), Apollo Palliative Services, and ApolloMed Care Clinics. ApolloMed is able to provide high quality, cost-effective care, and its revenue model ranges from traditional volume-based payments to taking full clinical and financial risk for pools of patients.
Apollo Medical Holdings (ApolloMed) is a leading integrated healthcare company providing solutions to hospitals, health plans, physicians, and other health providers to provide cost-effective, quality healthcare. We work with providers and hospitals to coordinate care with local primary care physicians to reduce preventable hospital admissions and re-admissions, best in class patient centric care, and avoidable emergency room visits.
Medical Affairs, as a function, sits at a crossroads in the pharmaceutical industry. The department is expected to act as a bridge between the commercial and scientific arms of an organization. Medical Affairs is further tasked with being the conduit of information between the company and external stakeholders, bringing efficacy and safety data to the medical community as well as gathering insights from the medical community to share internally. All responsibilities must be undertaken while keeping in mind strict regulatory controls and ensuring that medical data are interpreted appropriately.
ISR has designed this report to be used as a benchmarking tool for companies to compare their Medical Affairs functions to those of Top 50 pharmaceutical organizations.
See more: http://bit.ly/medaffairs
The document outlines a business plan for starting a medical device supply company in South Africa. It provides an overview of the market opportunity in South Africa, including growth rates in the medical device industry and the types of products sold. It then outlines 7 steps to starting the business, including selecting a niche market, obtaining necessary licenses and permits, setting up inventory, and marketing strategies. Key points about the South African market such as the size of the public and private hospital sector and available financing options are also summarized.
Easy-to-use web-based database enables users to generate custom reports based upon any combination of these variables: Brand, Therapeutic area, Company, Country and Time period.
Ambiance Ventures - Access to Emerging MarketsJay Nadkarni
The company provides market development and consulting services focused on emerging markets, especially those receptive to new life science technologies. It has offices in Brazil, Estonia, Finland, South Korea, and India to handle operations in Latin America, Europe, and Asia. The company has strong connections and relationships in various markets that enable it to expedite product launches and other business needs. It offers services such as market assessments, licensing opportunities, and developing partnerships and commercialization plans to help life science companies enter emerging markets.
Opexa Therapeutics is developing Tcelna, a precision immunotherapy for the treatment of multiple sclerosis (MS). Tcelna consists of attenuated antigen-specific T-cell clones that are designed to program the immune system to target pathogenic myelin reactive T-cells (MRTC) that cause damage in MS. Opexa has completed enrollment in a Phase IIb clinical trial of Tcelna in secondary progressive MS (SPMS) and expects top-line data in mid-2016. The company has an option agreement with Merck for the development and commercialization of Tcelna in MS that could provide up to $220 million in payments if certain development and sales milestones are achieved.
Genius Brands International provides children's entertainment content across multiple platforms. It owns established brands like Baby Genius that have found success in television, online, mobile, and consumer products. The company aims to produce content that is both entertaining and enriching for kids. It has an experienced management team with decades of experience in the children's entertainment industry. Genius Brands sees opportunities to expand its brands internationally and introduce new content partnerships with figures like Warren Buffett, Thomas Edison, and Stan Lee.
Energy Fuels is the nation's leading conventional uranium producer, supplying approximately 25% of the uranium produced in the U.S. (based on FY-2013 deliveries). The Company also has the capability to be a significant producer of vanadium. Energy Fuels owns and operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. The mill is capable of processing 2,000 tons per day of uranium ore and producing up to 8 million lbs. of U3O8 per year (depending on ore grade).
This document provides an overview and disclaimer for a company called Abakan Inc. It discusses Abakan's technology for applying corrosion-resistant coatings to pipes, which could address a multi-billion dollar market opportunity. The document outlines Abakan's intellectual property portfolio, recent development milestones, potential customers in various industries, and the large market size for addressing the global corrosion problem. It disclaims any promises or warranties regarding investment details and requests that the information be kept confidential.
Spherix generates revenue through acquiring and licensing patent portfolios. It has over 200 patents of its own covering various industries and is engaged in ongoing licensing campaigns. It has a relationship with Rockstar Consortium, which gives it access to over 4000 additional patents. Spherix recently acquired a portfolio of 222 patents from Harris Corporation covering 15 years of research across many technologies.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE and OncoCEE-BR, which measure circulating tumor cells. The document highlights Biocept's multi-faceted growth strategy including test menu expansion and increasing operational efficiency. It also introduces Biocept's executive team and discusses the large US market opportunity for cancer diagnostics.
Genius Brands International is a company focused on providing children's entertainment content with purpose for toddlers to tweens. It was created through the merger of A Squared Entertainment and Genius Brands. The document discusses Genius Brands' plans to grow its portfolio of animated properties like Baby Genius, Warren Buffett's Secret Millionaires Club, and new shows in partnership with Stan Lee and Martha Stewart. It aims to distribute this content across television, online, mobile and through a new streaming service, while supporting the content through consumer products licensing. The management team, including Andy and Amy Heyward, have decades of experience in the children's entertainment industry.
The document discusses Direct Insite, a company that provides cloud-based accounts payable and accounts receivable automation solutions. It notes that some statements may be forward-looking and discusses risks associated with such statements. It then provides an overview of Direct Insite's solutions, customers, and competitive advantages. Key points include its large network of over 450,000 suppliers and customers transacting over $130 billion annually, and its goal to achieve over 10% annual revenue growth through 2015 by expanding its sales force and introducing new products.
Senesco Technologies is developing a gene regulation technology to treat cancer. They are running a Phase 1b/2a clinical trial of their lead product, SNS01-T, to treat B-cell cancers like multiple myeloma and lymphoma. Preclinical studies show SNS01-T significantly inhibits tumor growth and improves survival in mouse models of these cancers. The presentation provides an overview of Senesco's technology, clinical trial status, financial information, and development plans to advance SNS01-T and expand to additional cancer indications.
The document discusses ChromaDex's forward-looking statements and FDA disclaimer. It then provides an overview of ChromaDex's mission to commercialize patented ingredient technologies, including nicotinamide riboside, pTeroPure, pterostilbene, and anthocyanins, in multi-billion dollar markets like dietary supplements and food and beverage. ChromaDex also has an established legacy business providing analytical testing services and natural products.
This document provides an overview of Big North Graphite Corp., a mining company exploring opportunities in Mexico and Canada. It discusses Big North's management team and board of directors, capital structure, and key investment highlights. Specifically, it outlines Big North's plans to accelerate re-starting operations at the historic Nuevo San Pedro Graphite Mine in Mexico, which produced amorphous graphite in the past. Big North acquired three past-producing graphite mines in Mexico and is working to resume production at Nuevo San Pedro.
Harris & Harris Group invests in transformative companies developing disruptive science and technology. It has a portfolio of 26 companies across various sectors including life sciences, electronics, and energy. Recent liquidity events from companies like Xradia that was acquired by Carl Zeiss have generated gains. The company aims to continue realizing value from its portfolio through partnerships and exits over the next few years to drive further growth.
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Opexa Therapeutics is developing Tcelna, a precision immunotherapy for the treatment of secondary progressive multiple sclerosis (SPMS). Tcelna consists of attenuated myelin-reactive T-cell clones that are designed to program the immune system to target pathogenic myelin-reactive T-cells. Opexa has an ongoing Phase IIb clinical trial of Tcelna in SPMS and expects to complete enrollment in mid-2014, with top-line data expected in mid-2016. Opexa has an option agreement with Merck for the development and commercialization of Tcelna in MS that could provide up to $220 million in payments.
Lightbridge Corporation is an innovative nuclear fuel technology company that has developed a new metallic nuclear fuel design. The new fuel design provides several benefits including increased power output from existing reactors, improved safety, and reduced costs. Lightbridge has validated the technology and economics through third-party analyses and has an MOU with Babcock & Wilcox to develop a pilot fuel fabrication plant. The company also has a successful nuclear advisory services business and plans to license the new fuel technology globally. Lightbridge has an experienced management team and board of advisors with extensive experience in the nuclear industry.
Oragenics is developing novel antibiotics and probiotics through synthetic biology collaborations. For antibiotics, they are focusing on lantibiotics, a class of naturally produced antibacterial peptides, to address the need for new antibiotics. Their lead compound MU1140 has shown efficacy against MRSA, VRE and C. difficile. For probiotics, they are engineering bacteria to deliver therapeutics locally in the oral cavity for diseases like canker sores and Behcet's disease. They also market the only patented probiotic for oral health called ProBiora3. Upcoming milestones include animal studies for MU1140 in 2014 and generating genetically modified probiotic prototypes in 2014-2015.
This document provides an overview of Galectin Therapeutics, a clinical stage biopharmaceutical company targeting fibrotic diseases and cancer. It summarizes the company's focus on developing galectin inhibitors, proteins that are important in fibrosis and cancer. Specifically, it outlines Galectin's development program for non-alcoholic steatohepatitis (NASH), a fatty liver disease, including preclinical evidence, current Phase 1 clinical trial testing safety and pharmacokinetics, and plans for a Phase 2 trial to evaluate efficacy in reducing liver fibrosis.
The document discusses the need for pharmaceutical companies to adopt key account management (KAM) as a new sales model. Changes in the US healthcare system over the past few decades, including the rise of integrated delivery networks and changes to insurance and payment models, have decreased pharmaceutical companies' influence over individual stakeholders. KAM is presented as an approach that can help pharmaceutical companies engage with larger healthcare organizations in a way that ensures brand development and sales in this new environment.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section tracking the performance of local publicly traded life sciences companies through an index and providing the top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards an exit through strategic sale or IPO.
- McKesson is a healthcare services company focused on pharmaceutical distribution and healthcare information technology. In FY2006, McKesson had revenues of $88.1 billion and net income of $751 million.
- The CEO discusses McKesson's role in transforming healthcare by improving cost, quality, safety, and efficiency through its scale, expertise, and technology. Key areas of focus include distribution, safety/error reduction, personal health management, spending healthcare dollars efficiently, supporting clinicians, and facilitating next-generation healthcare.
- Business segments saw strong growth in pharmaceutical distribution and healthcare IT, while the medical-surgical segment faced challenges in acute care that may require strategic changes. The CEO expresses confidence in McKesson
- McKesson is a healthcare services company focused on pharmaceutical distribution and healthcare information technology. In FY2006, McKesson had revenues of $88.1 billion and net income of $751 million.
- The CEO discusses McKesson's role in transforming healthcare by improving cost, quality, safety, and efficiency through its scale, expertise, and technology. Key areas of focus include distribution, safety/error reduction, personal health management, spending healthcare dollars efficiently, supporting clinicians, and facilitating next-generation healthcare.
- Business segments saw strong growth in pharmaceutical distribution and healthcare IT, while the medical-surgical segment faced challenges in acute care that may require strategic changes. The CEO expresses confidence in McKesson
This document discusses Quality Systems, Inc. and its subsidiary NextGen Healthcare Information Systems. It provides an overview of the company's business, markets served, products, growth strategy, financial performance, management team, and competitive advantages in the healthcare information technology industry. Key points include Quality Systems' focus on developing practice management and electronic health record software, its track record of strong revenue and earnings growth, experienced management team, and positioning to benefit from positive industry trends driven by government initiatives.
Michael T. Jordan has over 10 years of experience in sales and management in the healthcare industry. He has a proven track record of success growing sales territories, developing new business partnerships, and launching new product lines. His experience includes roles in medical device sales, independent contracting, and business ownership. He has extensive training and expertise in areas such as neuroscience, vascular studies, wound care, and operating room protocols.
McKesson Corporation is a leading healthcare services and distribution company. It operates through two main segments: Distribution Solutions and Technology Solutions. Distribution Solutions accounts for 98% of revenue and distributes pharmaceuticals and medical supplies in North America and Europe. Recent acquisitions like Celesio have expanded McKesson's international presence. The analyst recommends buying McKesson based on its industry leadership, recent acquisitions, and opportunities for growth in generic drug distribution and healthcare IT.
1) McKesson Corporation is a large healthcare services company that distributes pharmaceuticals and medical supplies. It recently acquired Celesio, expanding its European operations.
2) The company operates two segments - Distribution Solutions and Technology Solutions. Distribution Solutions accounts for 98% of revenue and involves pharmaceutical distribution in North America and internationally.
3) The industry outlook is positive due to demographics like an aging population and increasing chronic diseases. The acquisition of Celesio and expanded agreement with Rite Aid position McKesson well to benefit from growth in generic drug sales.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Kenneth Frank Elder Jr is a highly accomplished manager and representative in the pharmaceutical industry with over 21 years of experience. He has a proven track record of exceeding sales quotas and launching new products successfully. Currently he is a Federal Account Manager at Salix Pharmaceuticals focusing on therapeutic areas including cardiology, diabetes, women's health, and more. Previously he held several leadership and sales roles at GlaxoSmithKline and Novartis Vaccines where he received numerous awards and rankings for his performance. He has a bachelor's degree in marketing from Troy University.
This summary provides an overview of Stuart Allan Murray's background and experience in the biopharmaceutical industry over the past 25+ years. Murray has extensive experience leading commercial strategies for anti-infective products from early development through genericization. Most recently, he has been the president of his own consulting firm advising on product planning, commercialization, and optimizing asset value throughout the lifecycle. Prior to that, he held several leadership roles at Cubist Pharmaceuticals leading major product franchises and functions.
Craig Hoover is an experienced healthcare executive seeking a new leadership role. He has over 15 years of experience as a CEO, COO, and president for various healthcare organizations. Hoover has a track record of leading successful turnarounds, expansions, and startups. He focuses on improving quality of care, clinical outcomes, organizational excellence, and financial performance. Hoover's resume highlights his accomplishments in growing revenue and profits, implementing strategic initiatives, and maximizing operational efficiency across multiple healthcare settings.
Kristin Flowers is an experienced pharmaceutical sales executive seeking an oncology sales position. She has over 15 years of experience marketing diabetes and other pharmaceutical products for Merck, where she exceeded sales goals and received numerous awards for her performance. Flowers has a bachelor's degree in medical technology and relevant work experience in pathology laboratories.
Personal care physicians series b preferred investment presentationPersonalCare
The concierge medicine industry in the US is estimated at $5 billion and growing 34% annually. PersonalCare helps doctors, health systems, and companies provide optimal healthcare solutions to high-income customers. With over 1,800 paying members across 3 locations, PersonalCare generates over $8 million in annual recurring revenue and is trending towards positive EBITDA in Q4 2015. The company is seeking $1 million in funding to expand into new markets through physician partnerships and management agreements.
Jeffrey Shallcross is an experienced managed markets executive with over 30 years in the healthcare industry. He has held several leadership roles developing payer strategies and negotiating contracts to improve market access and sales for various pharmaceutical companies. Currently, Shallcross is the president of his own consulting firm, providing strategic guidance to organizations on managed markets opportunities.
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
This presentation provides an overview of NeoGenomics' proposed acquisition of Clarient, which would more than double NeoGenomics' revenue. The strategic rationale is that the combined company would have greater scale and a more balanced oncology product portfolio, allowing it to be a lower-cost provider. It would also gain a larger clinical trials business and enhanced geographic coverage. Synergies of $20-30 million annually are projected from consolidating laboratories, purchasing, cross-selling and other areas. The acquisition supports NeoGenomics' strategy of using M&A to accelerate its vision of becoming a leading cancer testing and information company.
Jennifer Wyckoff has over 15 years of experience in various healthcare roles including medical assistant, certified nurse's assistant, practice management, systems administration, and patient advocacy. She has a bachelor's degree in healthcare administration and an associate's degree in healthcare management. Wyckoff is proficient in electronic medical record systems, Microsoft Office, and network setup. She is seeking a position that utilizes her skills and passion for healthcare.
Strategic Management Presentation Final PPT Juan Valverde
This document analyzes the strategic position of Presence Mercy Medical Center. It conducts a situation analysis including a remote analysis of the healthcare industry, Porter's 5 forces analysis, and a SWOT analysis. It profiles Presence Mercy and its main competitor, Rush-Copley Medical Center. The document recommends a two-phase strategy. Phase one focuses on controlling costs through technology upgrades and developing physician relationships. Phase two suggests expanding services through new clinics in underserved areas to capture more market share from competitors like Rush-Copley.
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases. The Company launched two new clinical trials in 2021. Aptorum’s Smart-ACT™ platform is designed to bring an average of three drug candidates for orphan diseases to clinical trials every 12-18 months. The Company is now preparing to launch a dietary supplement for women undergoing menopause and experiencing related symptoms, including osteoporosis. Targeting a global woman’s health supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to generate near-term revenue with significant long-term growth potential.
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
This document provides an overview of Big North Graphite Corp., a mining company exploring graphite opportunities in Mexico and Canada. It summarizes the management team's experience, the capital structure including shares outstanding and warrants, and key investment highlights. Specifically, it notes Big North is currently selling amorphous graphite in Mexico and aims to restart near-term flake graphite production at its recently acquired El Tejon Flake Graphite Mine and Mill in Oaxaca, Mexico, which was previously operational until 2002. A cautionary note also indicates forward-looking statements may materially differ from expectations.
“The Coin Tree is a cloud-based storage, insurance, and payment processing platform for bitcoin that leverages cutting edge transactional security to serve the ever expanding virtual currency community."
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment aims to be a theatrical motion picture production and financing company focused on producing edgy, high quality films with strong casts and lean budgets. It mitigates risk through fiscal precision by financing projects once they are fully developed and ready to produce, offering investors a quicker return. Recent successful films include Lee Daniels' The Butler, Life of Crime, and Life After Beth.
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
- Bitcoin Shop is one of the first publicly traded companies focused on the virtual currency ecosystem. It operates an ecommerce platform that accepts bitcoin and other cryptocurrencies as payment.
- The company is developing its BTCS 2.0 platform to expand its product offerings and vendor base. It aims to build a virtual currency ecosystem through ecommerce.
- Bitcoin Shop has a experienced management team with expertise in capital markets, technology, and the virtual currency industry. It plans to grow its customer base and monetize through additional service offerings.
InterCloud Systems provides cloud-centric solutions and services to enterprises and service providers. Their two main business focus areas are Software Defined Enterprise and Cloud to Cloud Mobility. They help customers modernize infrastructure, develop cloud strategies, and deliver cloud-centric IT visions aligned to business value. InterCloud partners with major cloud platform and solution providers like VMware, OpenStack, and CloudStack.
This presentation provides an overview of SANUWAVE Health Inc., a regenerative medicine company developing non-invasive biological response activation devices. SANUWAVE's lead product, dermaPACE, is in a Phase III FDA trial for treating diabetic foot ulcers and has the potential for approval in 2015 pending positive results. DermaPACE offers a lower-cost, non-invasive alternative to existing wound therapies. If approved, dermaPACE could address the large diabetic foot ulcer market and be expanded to other applications. SANUWAVE completed a $9.3 million capital raise to fund the dermaPACE trial and has 38 patents covering its shockwave technology platform.
StationDigital is a digital media and ecommerce platform that allows users to stream or access any media and purchase digital and physical goods from any device. It has grown rapidly since its public beta launch in 2013, achieving over 1.3 million mobile users. The presentation outlines StationDigital's mission and growth strategy, competitive advantages over other media companies, and large market opportunity in digital media and ecommerce. It argues that StationDigital is well positioned for continued growth and market share capture.
DRONE Aviation Corp (DRNE) was formed in April 2014 to penetrate the rapidly growing Unmanned Aerial Systems (UAS) business in U.S. and abroad for government and commercial customers.
DRNE’s mission is to aggressively penetrate the expanding Drone market with our unique Tethered Drones, which are currently being fielded to the U.S. Department of Defense and State and Local municipalities.
DRNE owns and operates Florida-based Lighter Than Air Systems Corp (LTAS), a developer and supplier of unique and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
InterCloud Systems Incorporated is a single - source provider of end - to - end IT technology and telecom solutions to the ent erprise, service provider, and g overnment markets through “Cloud Platforms” and professional services. “Cloud Comput ing”, is defined as the use of computing resources (compute, NTK, Storage) that are delivered as a managed service over a network. InterCloud offers its service provider custo mers the ability to utilize “cloud” solutions inside their existing network footp rint as well as in a “white label environment” so it can offer a suite of cloud products under their own brand, delivered over the broadband services it presently sell s . ICLD’s cloud services include infrastructure as a service (IaaS), platform as a servi ce (PaaS), and software as a service (SaaS) .
This document provides an overview of Actinium Pharmaceuticals, Inc. and summarizes their proprietary alpha particle immunotherapy technology and product pipeline. Key points include:
1) Actinium has a pipeline of targeted radiotherapy candidates using alpha emitters to treat various blood cancers. Their lead candidate, Iomab-B, is being developed for conditioning blood cancer patients prior to bone marrow transplant.
2) Iomab-B has shown promising results in clinical trials, successfully preparing older refractory AML patients for transplant who otherwise would not be eligible. Actinium has FDA agreement to advance Iomab-B into a Phase III registration trial.
3) Actinium has a proprietary technology
Richfield Oil & Gas Company (OTCQX: ROIL) is an independent exploration and production company headquartered in Salt Lake City, Utah. The Company’s current oil production flows from wells in fields located in Kansas and Wyoming. In addition to several thousand acres in Kansas, Richfield also owns strategically-located exploratory leases in central Utah on trend to major oil discoveries.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
American Water provides water and wastewater services to approximately 14 million people in 16 states, has a market capitalization of $8.6 billion, and seeks to continue growing its regulated water business through capital investments and acquisitions while also expanding its complementary market-based business lines. The company has delivered strong total shareholder returns since its 2008 IPO and maintains a transparent dividend policy aimed at increasing its dividend in line with normalized earnings per share growth.
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
Direct Insite (“DIRI”) provides cloud-based, ERP-agnostic solutions that automate Accounts Payable (AP) and Accounts Receivable (AR) invoice processes for Global 3000 companies. Their solutions include invoice validation, order matching, consolidation, dispute handling and e-payment processing. DIRI helps clients eliminate manual processes and costs associated with doing everything on paper. By migrating from paper to electronic, DIRI can reduce transactions costs 50-70% and reduce time by 80%. Current clients include Siemens, HP, IBM, Saint-Gobain, Shell Oil, and Hyatt with a Global vendor network of 350,000+ suppliers.
Lattice Incorporated (“Lattice” or the “Company”), founded in 1973, provides secure communications and information technology, specializing in deploying advanced technology and services to create innovative, cost - effective solutions for the Company’s global customers. The Company provides both wholesale and direct services to correctional facilities and their service providers in the U.S., Canada and Europe. Expansion of Lattice’s direct and wholesale services, including increased techno logy equipment and software sales to wholesale customers, is expected to drive revenue growth and increased margins in the quarters ahead
Quadrant 4 Systems Corporation is a leading provider in of health exchange platforms, innovative software products and proprietary SMAC (social media, mobility, analytics and cloud computing) solutions to enterprise clients in Retail and Manufacturing, Media and Publishing, Financial Services and Health Care sectors.
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
2. Safe
Harbor
This
presenta,on
and
our
discussion
contains
forward-‐looking
statements
within
the
meaning
of
the
"safe
harbor"
provisions
of
the
Private
Securi,es
Li,ga,on
Reform
Act
of
1995.
These
forward-‐looking
statements
are
based
on
the
Company’s
current
expecta,ons,
es,mates
and
projec,ons
about
the
Company,
management’s
beliefs,
and
certain
assump,ons
made
by
the
Company,
and
events
beyond
the
Company’s
control,
all
of
which
are
subject
to
change.
Forward-‐looking
statements
can
oKen
be
iden,fied
by
words
such
as
“an,cipates,”
“drive,”
“focus,”
“expects,”
“intends,”
“plans,”
“predicts,”
“believes,”
“seeks,”
“es,mates,”
“may,”
“will,”
“should,”
“would,”
“could,”
“likely,”
“poten,al,”
“con,nue,”
“ongoing,”
similar
expressions,
varia,ons
or
nega,ves
of
these
words.
These
forward-‐looking
statements
are
not
guarantees
of
future
results,
and
they
are
subjected
to
risks,
uncertain,es
and
assump,ons
that
could
cause
actual
results
to
differ
materially
and
adversely
from
those
expressed
in
any
forward-‐looking
statement.
The
risks
and
uncertain,es
referred
to
above
include,
but
are
not
limited
to,
market
acceptance
of
the
Company’s
test
offerings,
the
Company’s
ability
to
grow
and
expand
its
business,
success
in
launching
new
strategic
partnerships
and
alliances,
the
Company’s
ability
to
raise
addi,onal
capital
on
a
,mely
basis,
or
at
all,
or
to
improve
its
opera,ng
results
in
the
near
future;
and
such
other
factors
described
in
the
Company’s
filings
with
the
Securi,es
and
Exchange
Commission.
The
forward-‐looking
statements
in
this
presenta,on
speak
only
as
of
the
date
they
are
made.
The
Company
undertakes
no
obliga,on
to
revise
or
update
any
forward-‐looking
statement
for
any
reason.
2
3. CombiMatrix
–
A
Healthcare
Services
Company
Strategy
Technology
Management
Team
Provide
data
and
clinical
support
to
clinicians
and
pathologists
in
the
areas
of
prenatal
gene,cs,
pediatric
developmental
disorders
and
oncology
Microarray
plaTorms,
karyotyping,
and
FISH
for
elucida,ng
gene,c
anomalies
in
the
cytogene,c
arena
Leadership
has
extensive
experience
in
diagnos,c
industry
• Strategic
refocus
in
2012
to
prenatal
and
pediatric
segments
• A
leader
in
microarray
tes,ng
with
over
25,000
tests
performed
• New
commercial
and
medical
leadership
in
2012
• Building
sales
force
and
strategic
partnerships
to
drive
volume
• Provides
informa,on
on
specific
disease
and
clinical
manifesta,ons
for
improved
pa,ent
care
• Headquarters
in
Irvine,
CA
• LTM
revenue:
$5.9M
(as
of
6/31/13)
Comprehensive
Service
Solu;ons
for
Clinicians
MFM*
Clinics
•
Ob-‐Gyn
Clinics
•
Oncologists
•
Payer
Systems
•
Reference
Labs
!
!
!
Apply
cuRng
edge
technologies
to
g
enerate
gene,c
data
Timely
transmission
of
reports
in
an
easy-‐to-‐read
format
Provide
best-‐in-‐class
post-‐test
support
to
health
care
providers
*
MFM
stands
for
Maternal
Fetal
Medicine
3
4. Management
Team
Mark
McDonough
–
President
&
CEO
! Served
as
VP
of
U.S.
Sales,
Customer
Service
and
Training
at
Pathwork
Diagnos,cs
! Served
various
roles
including
District
and
Regional
Manager,
and
VP,
Sales
of
U.S.
LABS,
Inc.,
which
was
acquired
by
Laboratory
Corp.
of
America
Holdings
(NYSE:LH)
for
$155.0
million.
He
earned
the
dis,nc,on
of
being
named
District
Manager
of
the
Year
and
Regional
Manager
of
the
Year
in
consecu,ve
years
prior
to
his
promo,on
to
Vice
President.
! Served
in
various
Management
and
Specialty
Sales
posi,ons
at
Ventana
Medical
Systems,
a
healthcare
equipment
company
that
was
acquired
by
Roche
Holding
AG
(SWX:ROG)
for
$3.4
billion;
and
EMC
Corpora,on-‐Hopkinton,
MA.
! B.S.
in
Finance
from
Miami
University
(Ohio)
Rick
HockeL,
M.D.
–
Chief
Medical
Officer
! Served
as
Vice
President
and
Chief
Medical
Officer
at
Affymetrix
! Served
as
Director
of
Genomic
Medicine
at
Eli
Lilly
! M.D.,
University
of
Minnesota
ScoL
Burell
–
Chief
Financial
Officer
! Has
held
various
roles
at
the
Company
including
Secretary,
Treasurer,
Vice
President
of
Finance,
and
Controller
! Served
as
Controller
for
Network
Commerce,
Inc.
! Served
at
Arthur
Andersen's
Audit
and
Business
Advisory
prac,ce
for
9
years.
! B.S.
in
Accoun,ng
and
Finance
from
Central
Washington
University.
4
5. Recent
Highlights
Summary
of
Recent
News
Events
Date
Milestones
• ACOG
recommends
Microarray
analysis
as
first-‐line
gene,c
tes,ng
over
Karyotyping
• Launch
of
Sequenom
/
CombiMatrix
partnership
to
market
Prenatal
microarray
tes,ng.
• 3rd
Quarter
2013
results:
2013:
Q4
− Quarterly
growth
in
prenatal
microarray
tes4ng
volumes
and
revenues
of
140%
&
129%
for
Q3-‐2013
over
Q3-‐2012
− Quarterly
revenue
of
$1.5
million,
up
16%
from
Q3-‐2012
2013:
Q3
• 2nd
Quarter
2013
results:
− Quarterly
growth
in
prenatal
microarray
tes4ng
volumes
and
revenues
of
156%
&
152%
for
Q2-‐2013
over
Q2-‐2012
− Quarterly
revenue
of
$1.5
million,
up
15%
from
Q2-‐2012
2013:
Q2
• 1st
Quarter
2013
results:
₋ Quarterly
growth
in
prenatal
tes4ng
volumes
and
revenues
of
124%
&
158%
for
Q1-‐2013
over
Q1-‐2012
₋ Quarterly
revenue
of
$1.6
million,
up
9%
from
Q4-‐2012.
2013:
Q1
• Fiscal
Year
2012
results:
− Revenue
increased
15%
to
$5.4
million
over
FY
2011
− Prenatal
tes4ng
revenue
increased
by
more
than
101%
vs.
FY
2011
• Mark
McDonough
appointed
as
new
CEO
2012:
Q4
2012:
Q1
–
Q3
5
• Two
ar,cles
published
in
the
New
England
Journal
of
Medicine
document
favorable
clinical
u,lity
from
using
microarrays
over
tradi,onal
tes,ng
in
both
the
prenatal
and
miscarriage
management
markets.
• Mark
McDonough
joins
CombiMatrix
as
Chief
Commercial
Officer
to
lead
and
build
sales
team
to
grow
its
prenatal
and
pediatric
businesses.
• Richard
Hockeu,
Jr.,
M.D.
joins
CombiMatrix
as
Chief
Medical
Officer,
providing
cri,cal
microarray
exper,se
and
leadership
to
the
Company’s
leadership
team.
8. Prenatal
Diagnos;c
Tes;ng
Customers
Medical
Benefits
Maternal
Fetal
Medicine
specialists
(MFM)
!
!
OB/GYNs
!
!
Gene,c
Counselors
!
!
Provides
high
resolu,on
diagnosis
of
cytogene,c
disorders
Allows
parents
to
make
informed
decisions
on
pregnancies
Recently
published
NICHD
study
supports
microarrays
over
karyotyping
for
prenatal
tes,ng
Compe;;ve
Advantages
!
!
!
!
!
8
A
pioneer
of
direct
microarray
analysis
of
amnio,c
fluid
and
CVS.
Rapid
7-‐day
turn
around
,me
All
tests
performed
in
one
loca,on
CombiCounsel™
Gene,c
Counseling
Program
Unique
counseling
and
physician
summary
reports
9. Jim
Goldberg
–
MFM
Key
Opinion
Leader
“The
NIHCD
study
clearly
demonstrated
the
superiority
of
microarrays
over
tradi,onal
karyotyping”,
said
Jim
Goldberg,
MD
of
San
Francisco
Perinatal
Associates.
“Due
to
the
strength
of
the
data
in
that
study,
we
now
counsel
pa,ents
on
the
availability
of
microarray
tes,ng
and
offer
this
op,on
to
them
as
a
first
,er
test.”
Dr.
Goldberg
reiterated
“ The
clinical
u,lity
of
microarrays
are
their
ability
to
detect
chromosomal
copy
number
abnormali,es
that
are
missed
by
tradi,onal
karyotyping.
The
accuracy
of
microarray,
coupled
with
the
test’s
fast
turn-‐around-‐,me,
helps
reduce
pa,ents’
anxiety
by
providing
comprehensive
results
as
we
move
toward
this
new
standard
of
care.”
9
10. Comprehensive
Prenatal
Tes;ng
Solu;on
Microarray
is
Complementary
to
NIPS
Chromosomal
Microarray
• ACOG
recommends
all
posi,ve
NIPS
screens
receive
invasive
tes,ng
• Microarray
is
proven
to
be
test
of
choice
aKer
invasive
procedure
(NIHCD
study,
Dec
2012
NEJM)
10
Non-‐Invasive
Prenatal
Screening
(NIPS)
• Screening
test
for
aneuploidies
of
chromosomes
13,
18,
21,
X
&
Y
• Expect
over
375,000
NIPS
tests
to
be
run
in
2013;
run
rate
is
growing
at
480,000
• Reflex
to
invasive
tes,ng
an,cipated
to
be
~5%
11. Executed
Payor
Contracts
Date
Payor
Group
Covered
Lives
2013:
Q4
• FedMed
Na4onal
Provider
Network
• America’s
Choice
Provider
Network
• Blue
Cross
and
Blue
Shield
of
Kansas
City
• Three
Rivers
Provider
Network
• 40
million
• 14
million
• 800,000
• 15
million
2013:
Q3
• Blue
Shield
of
California
• 3
million
• Mul4plan
• 57
million
2012
11
12. Sequenom
Partnership
–
Press
Release
! We have established several key partnerships in the past year, most notably with Sequenom, Inc., where we jointly
announced in August 2013, that we entered into a collaboration agreement to market and promote chromosomal
microarray analysis (or “CMA”) to broaden and confirm the results of NIPS for physicians and their patients. Under
this agreement, our two companies will collaboratively use our respective marketing channels and sales forces to
promote the use of NIPS and CMA and work together to provide technical training to physicians and counseling,
education and support services to expectant parents. Our two companies plan to provide, when clinically
appropriate, a comprehensive test results report for physicians and parents.
! “The collaboration with Sequenom is a significant validation of the rapidly expanding acceptance of CMA as a
standard of prenatal care as well as an endorsement of the services CombiMatrix provides,” noted CombiMatrix
CEO Mark McDonough.
! “We are focused on establishing CombiMatrix as the premier specialty laboratory for chromosomal microarray
analysis for prenatal testing,” McDonough said. “The fact that Sequenom has joined forces with us and selected us
for this collaborative testing relationship demonstrates that we have made great strides in reaching our goal.”
12
13. Miscarriage
and
S;llbirth
Tes;ng
Customers
!
Maternal
Fetal
Medicine
specialists
(MFM)
!
OB/GYNs
!
Pathologists
!
Reproduc,ve
Endocrinologists
Medical
Benefits
!
!
!
Microarray
provides
high
resolu,on
diagnosis
of
gene,c
disorders,
which
account
for
50%
of
miscarriages
occurring
prior
to
20
weeks
gesta,on.
Avoid
costly
evalua,ons
of
mother,
if
chromosomal
e,ology
uncovered,
saving
$500
-‐
$1,200
per
pa,ent*.
Allows
parents
to
make
informed
decisions
on
future
pregnancies
by
enabling
the
refinement
of
risk
for
addi,onal
pregnancy
loss
Compe;;ve
Advantages
!
!
!
!
!
!
Mul,ple
plaTorms,
to
enable
analysis
of
fresh
and
FFPE
POC
samples
Rapid
turn
around
,me
(7-‐10
days).
All
tests
performed
in
1
loca,on
High
success
rates:
95%
from
fresh
POC
and
93%
FFPE
POC
Unique
extended
counseling
and
physician
summary
reports
Ready
access
to
medical
staff,
to
answer
technical
and
clinical
inquiries.
*Foyouzi,
et
al.
Fer,l
Steril
2012;98:151-‐155
Bernardi,
et
al.
Fer,l
Steril
2012;98:156-‐161
13
14. Growing
Prenatal
Microarray
Services
Business
Volumes
$1,000
273%
Volume
Increase
546
500
387
300
213
200
145
168
225
271%
Revenue
Increase
$836
$836
$847
$800
461
400
#
of
Tests
541
$
in
Thousands
600
Revenues
($
in
‘000s)
$660
$600
$400
158
$313
$331
$370
$228
$232
$200
100
0
Q3'11
Q4'11
Q1'12
Q2'12
Q3'12
Q4'12
Q1'13
Q2'13
Q3'13
Refocused
commercial
strategy
$0
Q3'11
Q4'11
Q1'12
Q2'12
Q3'12
Q4'12
Q1'13
Q2'13
Q3'13
Refocused
commercial
strategy
Management’s
strategic
shiW
in
mid-‐2012
to
focus
company
resources
on
its
prenatal
services
has
resulted
in
record
tes4ng
volumes
and
rapid
revenue
growth
14
16. Near-‐Term
Catalysts
for
Growth
&
Profitability
Fast
Growing
Molecular
Diagnos;cs
Market
! New
tes,ng
algorithms
driven
by
molecular
tes,ng
! Data
published
suppor,ng
microarray
technology
as
superior
(NIHCD
study
in
NEJM)
Consolida;ng
Market
Creates
Opportuni;es
in
the
Industry
! Disrup,on
of
exis,ng
client
rela,onships
! Mul,ple
recent
transac,ons
Revenue
Cycle
Management
! Internalized
Billing
/
Collec,on
solu,ons,
thus
driving
faster
revenue
capture
Three
Pronged
Commercial
Strategy
to
op;mize
Prenatal
Market
Growth
! Direct
sales
force
! Industry
partners-‐
Plan
to
leverage
industry
partners
to
lower
cost
of
sales,
drive
adop,on,
and
complete
the
offering
! Regional
and
na,onal
pathology
lab
partners-‐
Plan
to
leverage
them
to
lower
cost
of
sales,
drive
adop,on
quickly
16
17. Plans
to
Deploy
Recent
Capital
Investment
! Sales
force
expansion
! Test
menu
and
new
market
expansion
! Managed
care
team
expansion
! Partnership
opportuni,es
! Interna,onal
distribu,on
17
18. Summary
! CombiMatrix
provides
valuable
molecular
diagnos,c
solu,ons
that
include
advanced
DNA-‐based
assays,
and
comprehensive
clinical
support
and
customer
service
for
the
highest
quality
of
care
–
specializing
in
miscarriage
management
on
POCs,
prenatal,
and
pediatric
healthcare
! Execu,ng
on
the
expanding
Prenatal
tes,ng
market
that
has
followed
the
publishing
of
the
recent
NICHD-‐sponsored
study
endorsing
microarray
tes,ng
! Op,mizing
and
expanding
the
Sales
organiza,on
! Implemented
cost
control
measures
and
efficiency
improvements
! Experienced
management
team
! Mul,-‐specialty
DNA-‐based
genomic
tes,ng
services
addressing
large
and
growing
prenatal,
pediatric
and
oncology
markets
18